低剂量地西他滨序贯改良CAG方案治疗骨髓增生异常综合征致ASXL1和U2AF1基因突变转阴一例并文献复习
Journal of Leukemia and Lymphoma(2019)
Abstract
目的 探讨去甲基化药物地西他滨针对骨髓增生异常综合征(MDS)表观遗传学调节基因的敏感性.方法 回顾性分析兰州军区兰州总医院1例低剂量地西他滨序贯改良CAG方案治疗MDS使突变基因ASXL1和U2AF1转阴患者的临床资料,并复习相关文献.结果 该患者经低剂量地西他滨联合半量CAG方案化疗,表观遗传学调节子突变基因ASXL1和U2AF1转阴,临床症状缓解,血象逐渐恢复正常,骨髓象完全缓解.结论 地西他滨可使MDS阳性表观遗传学调节子ASXL1和U2AF1基因突变转阴.
MoreTranslated text
Key words
myelodysplastic syndromes,u2af1 mutations,asxl1,modified cag regimen,low-dose
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined